Dr. Veena Shankaran, co-director of Fred Hutch’s health care and economics policy research group, the Hutchinson Institute for Cancer Outcomes Research, commented on the impact of high-deductible health plans on people with cancer. She said, “high-deductible plans are really the epitome of the access-to-care problem. People don't have the liquid cash to meet their deductible, so you see delays in care or even avoiding treatment altogether.”
Fred Hutch Dr. Jonathan Wright provided expert commentary on the relationship between excess weight and cancer risk. Dr. Wright is currently conducting a trial on overweight patients with low-grade, slow growing prostate cancer to see if monitoring their glucose levels through a weight loss period will improve their cancer outcomes.
In this Q&A, Dr. Nancy E. Davidson, director of Fred Hutch’s Clinical Research Division and executive director and president of Seattle Cancer Care Alliance, discussed the latest breast cancer research and what has been learned so far in clinical trials for epigenetic therapies.
FierceBiotech highlighted work conducted by Dr. Kristin Anderson in Dr. Phil Greenberg’s lab on immunotherapy in ovarian cancer. The results, which were presented at the 2019 American Association for Cancer Research annual meeting showed that when combining engineered T cells with two other immune boosting treatments, the growth of ovarian tumors in mice was decreased.
CURE profiled Dr. Gary Lyman and a New England Journal of Medicine study he co-authored that evaluated a drug’s safety and efficacy in preventing blood clots in cancer patients. The results from this study, known as the CASSINI trial, showed that the drug may reduce the risk of blood clots in cancer patients.
Fred Hutch’s Dr. Jesse Bloom commented on a study evaluating the early development of a new antiviral drug for influenza. He said, “We need more drugs in the fight against flu, and this approach could provide them."
Vishavjit Singh, a political cartoonist, performance artist and activist visited Fred Hutch to discuss how to confront biases and celebrate diversity and inclusion. This piece highlights his visit and the efforts at Fred Hutch to foster a supportive and inclusive scientific community.
Fred Hutch virologist Dr. Keith Jerome provided context around news of the second person who reportedly has been cured of HIV. He commented, “Now there’s not one, but two people that others living with HIV can look toward for encouragement.”
KING 5 aired multiple stories on Dr. Jonathan Bricker’s efforts to help cancer patients quit smoking and to support the Washington state tobacco 21 bill which will raise the age of smoking from 18 to 21. The bill was signed into law at Fred Hutch on April 5th.
In this profile piece, Eric Nealy, a graduate research assistant in Dr. Jim Olson’s lab, discusses how with the help of his mom, his high school biology teacher, and the only African American science professor he could find at college helped him pursue a career in cancer research.
This article features a recent study by Fred Hutch researcher Dr. Scott Ramsey published in JAMA Oncology which found that many cancer patients were had undiagnosed Hepatitis B and C and HIV infection.
Dr. Jordan Gauthier explains his findings on a combination immunotherapy treatment. Gauthier and his team found that adding the targeted therapy drug ibrutinib to CAR T-cell therapy led to improved responses in patients with relapsed/refractory chronic lymphocytic leukemia.
This article features Dr. Gary Lyman’s recent research published in the New England Journal of Medicine. This was the first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk.
Dr. Victor Chow explains different treatment settings that CAR T-cell therapy is used in patients with B-cell lymphomas. He states that, “While CAR T cells have been approved for treatment of individuals after two or more lines of therapy, studies are now looking at moving this to the upfront setting.”
This article notes research led by Dr. Justin Taylor using CRISPR, a gene-editing tool, to fight viruses when vaccines can’t. Taylor explained how his team has been investigating CRISPR as a tool to edit B cells in mice that could synthesize antibodies against respiratory syncytial virus (RSV).
This article features Dr. Joe Unger’s recent study on barriers to clinical trials. Unger’s study showed that structural and clinical barriers prevent more than 3 out of 4 cancer patients from participating in clinical trials.
This article on new techniques to detect minimal residual disease includes expert commentary by Dr. Mary-Percival and highlights trials that are going on at Fred Hutch to examine personalized cell therapies for treating MRD in different blood cancers.
Dr. Keith Jerome is featured in a story of research progress in treating herpes. He explains how his work with the gene editing tool – a class of enzymes called meganucleases – is showing more success in getting rid of the virus.
This article features recent HIV research from Fred Hutch Drs. Jesse Bloom and Julie Overbaugh. Researchers have created an atlas of immune-evading mutations HIV mutations, providing insight on the functional interactions between antibodies and HIV.
This article features research led by Fred Hutch researcher Dr. Anne McTiernan showing that women who exercised for 45 minutes in the morning 5 days a week reported 70 percent better sleep than before the study.
Fred Hutch researcher Drs. Keith Jerome, Hans-Peter Kiem and Michael Louella, who coordinates the research group’s Community Advisory Board, provide expert comments on the importance of community engagement in HIV research.
Fred Hutch researcher Dr. Anne McTiernan is featured in this segment for her research on exercise in relation to breast cancer prevention. Dr. McTiernan found that moderate exercise, 45 minutes a day, 5 days a week, can reduce breast cancer risk by as much as 20%.
This article features Fred Hutch researcher Dr. Parth Shah’s latest research on HPV vaccination. Dr. Shah found that parents were more confident in HPV vaccination and more motivated to have their child vaccinated by being exposed to physician messages that provided information rather than a sense of urgency.
This article highlights a recent study which found a high rate of undiagnosed acute and chronic hepatitis among cancer patients. Fred Hutch researcher Dr. Scott Ramsey provides expert commentary on the implications the study has in terms of screening. U.S. News & World Report also covered this study.
This story features the Seattle Flu Study, a new project from the Brotman Baty Institute which was co-founded by Seattle Children’s, UW Med and Fred Hutch. The study will look at 10,000 swabs to better understand how the flu spreads and how to prevent it. Fred Hutch’s Dr. Trevor Bedford is the lead data scientist for the study.
Dr. Cyrus Ghajar’s latest research on metastatic breast cancer is the focus of this piece. Dr. Ghajar’s work details how to kill dormant breast cancer cells in their sleep. Several other outlets including GeekWire, KOMO-TV and FireceBiotech also covered this news.
Dr. Geoffrey Hill and collaborators in Australia discovered how a common virus called cytomegalovirus reactivates in transplantation patients. In a study published in Science, the researchers found that strain-specific antibodies made from B cells are responsible for keeping CMV suppressed in mice, without the need for any other immune cells.
This article features Dr. Joseph Unger’s recent study in JAMA Oncology on clinical trial participation. Dr. Unger shows that patients with comorbidities are less likely to participate in clinical trials.
This piece features Fred Hutch Dr. Joseph Unger’s latest research showing that expanding clinical trial eligibility criteria to allow patients with comorbidities would give opportunities for up to 6,317 cancer patients to be allowed to join a trial every year.
Fred Hutch researcher Dr. Joseph Unger’s latest research on clinical trial participation is featured in this piece. Dr. Unger and his team showed that cancer patients with other illnesses or conditions, are less likely to be offered to join a clinical trial, and therefore less likely to enroll. This research was published in several other outlets including Healio, Medical Health News and MedPage Today.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.